Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders

Antioxidants and Redox Signaling

Volumn 8, Issue 11-12, 2006, Pages 1997-2006

  Mattson, Mark P ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIOXIDANT; CASPASE; CHAPERONE; HUNTINGTIN; NEUROTROPHIC FACTOR; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; APOPTOSIS; CALCIUM HOMEOSTASIS; CELL SURVIVAL; DEGENERATIVE DISEASE; DIETARY INTAKE; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; GENETIC MANIPULATION; HUMAN; HUNTINGTON CHOREA; LIFESTYLE; LIPID OXIDATION; MITOCHONDRION; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; NERVE CELL;

ANIMALS; APOPTOSIS; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 33947623671     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2006.8.1997     Document Type: Review

References (148)

1. Alexianu ME, Mohamed AH, Smith RG, Colom LV, and Appel SH. Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J Neurochem 63:2365-2368, 1994.
2. Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, Carvalho RF, Carvalho AP, and Duarte CB. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and P13-kinase pathways. Cell Death Differ 12: 1329-1343, 2005.
3. Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Arrenius S, Lipton S, and Nicotera P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15: 961-973, 1995.
4. Ay I, Sugimori H, and Finklestein SP. Intravenous basic fibroblast growth factor (bFGF) decreases DNA fragmentation and prevents downregulation of Bcl-2 expression in the ischemic brain following middle cerebral artery occlusion in rats. Mol Brain Res 87: 71-80, 2001.
5. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, Snyder SH, and Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47:29-41, 2005.
6. Barzilai A and Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med 9: 126-132, 2003.
7. Bendotti C and Carri MT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med 10: 393-400, 2004.
8. Bhave SV, Ghoda L, and Hoffman PL. Brain-derived neurotrophic factor mediates the anti-apoptotic effect of NMDA in cerebellar granule neurons: signal transduction cascades and site of ethanol action. J Neurosci 19: 3277-3286, 1999.
9. Boehning D, Patterson RL, and Sedaghat L, et al. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol 5: 1051-1061, 2003.
10. Borlongan CV, Koutouzis TK, and Sanberg PR. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev 21:289-293, 1997.
11. Bove J, Prou D, Perier C, and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2: 484-494, 2005.
12. Bredesen DE. Apoptosis: overview and signal transduction pathways. J Neurotrauma 17: 801-810, 2000.
13. Bruce-Keller AJ, Umberger G, McFall R, and Mattson MP. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann Neurol 45: 8-15, 1999.
14. Bruijn LE, Miller TM, and Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723-749, 2004.
15. Brunet A, Sweeny LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostaoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015, 2004.
16. Buj-Bello A, Pinon LG, Davies AM. The survival of NGF-dependent but not BDNF-dependent cranial sensory neurons is promoted by several different neurotrophins early in their development. Development 120: 1573-1580, 1994.
17. Bullock R. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord 20:23-29, 2006.
18. Camandola S, Cutler RG, Gary DS, Mulhavet O, Mattson MP. Suppression of calcium release from inositol 1,4,5-trisphosphate-sensitive stores mediates the anti-apoptotic function of nuclear factor-kappaB. J Biol Chem 280: 22287-22296, 2005.
19. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 20: 589-599, 2000.
20. Chan SL, Culmsee C, Haughey N, Klapper W, Mattson MP. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol Dis 11: 2-19, 2002.
21. Chang LK, Schmidt RE, Johnson EM Jr. Alternating metabolic pathways in NGF-deprived sympathetic neurons affect caspase-independent death. J Cell Biol 162: 245-256, 2003.
22. Cheng B and Mattson MP. NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron 7: 1031-1041, 1991.
23. Cheng B and Mattson MP. IGF-I and 1GF-1I protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J Neurosci 12: 1558-1566, 1992.
24. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Mascone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, and Ross CA. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7: 783-790, 1998.
25. Cracker SJ, Liston P, Anisman H, Lee CJ, Smith PD, Earl N, Thompson CS, Park DS, Korneluk RG, and Robertson GS. Attenuation of MPTP-induced neurotoxicity and behavioural impairment in NSE-X1AP transgenic mice. Neurobiol Dis 12: 150-161, 2003.
26. Crow JP, Calingasan NY, Chen J, Hill JL, and Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258-265, 2005.
27. Culmsee C and Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun 331: 761-777, 2005.
28. Cutler RG, Pedersen WA, Camandola S, Rothstein JD, and Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 52: 448- 457, 2002.
29. Cutler RG, Kelly J, and Pedersen WA, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 101: 2070-2075, 2004.
30. De la Monte SM, Sohn YK, and Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152: 73-83, 1997.
31. De Pril R, Fischer DF, Maat-Schieman ML, Hobo B, de Vos RA, Brunt ER, Hol EM, Roos RA, and van Leeuwen FW. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 13: 1803-1813, 2004.
32. Dodart JC, Mathis C, Bales KR, and Paul SM. Does my mouse have Alzheimer's disease? Genes Brain Behav 1: 142-155, 2002.
33. Dragunow M, MacGibbon GA, and Lawlor P, et al. Apoptosis, neurotrophic factors and neurodegeneration. Rev Neurosci 8: 223-265, 1997.
34. Duan W, Zhang Z, Gash DM, and Mattson MP. Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann Neurol 46: 587-597, 1999.
35. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, Cutler RG, Cadet JL, Greig NH, and Mattson MP. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 52: 597-606, 2002.
36. Duan W, Guo Z, Jiang H, Ware M, Li XJ, and Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A 100: 2911-2916, 2003.
37. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, and Beckman JS. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 286: 2498-2500, 1999.
38. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, and Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20: 4389-4397, 2000.
39. Fleming SM, Fernagut PO, and Chesselet MF. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2: 495-503, 2005.
40. Frank KM, Sharpless NE, Gao Y, Sekiguchi JM, Ferguson DO, Zhu C, Manis JP, Horner J, DePinho RA, and Alt FW. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 5: 993-1002, 2000.
41. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348: 1365-1375, 2003.
42. Gibson GE and Huang HM. Mitochondrial enzymes and endoplasmic reticulum calcium stores as targets of oxidative stress in neurodegenerative diseases. J Bioenerg Biomembr 36: 335-340, 2004.
43. Giffard RG, Xu L, Zhao H, Carrico W, Ouyang Y, Qiao Y, Sapolsky R, Steinberg G, Hu B, Yenari MA. Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury. J Exp Biol 207: 3213-3220, 2004.
44. Gilman CP and Mattson MP. Do apoptotic mechanisms regulate synaptic plasticity and growth cone motility? Neuromol Med 2: 197-214, 2002.
45. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Baillancourt JP, and Hayden MR. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13: 442-449, 1996.
46. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76: 126-152, 2005.
47. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, and Mattson MP. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. J Neurosci 17: 4212-4222, 1997.
48. Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, Bondada V, Rangnekar VM, and Mattson MP. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat Med 4: 957-962, 1998.
49. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM, and Mattson MP. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci U S A 96: 4125-4130, 1999.
50. Guo Q, Sebastian L, Sopher BL, Miller MW, Ware CB, Martin GM, and Mattson MP. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J Neurochem 72: 1019-1029, 1999.
51. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Tumel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, and Hirsch EC. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97: 2875-2880, 2000.
52. Hassouna I, Wickert H, Zimmermann M, and Gillardon F. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett 204: 85-88, 1996.
53. Hickey MA and Chesselet MF. Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 255-265, 2003.
54. Hiona A and Leeuwenburgh C. Life-long caloric restriction counteracts apoptotic effects of aging in the brain and bolsters the action of apoptosis inhibitors. Neurobiol Aging 26: [Epub ahead of print], 2005.
55. Hoehn B, Yenari MA, Sapolsky RM, and Steinberg GK. Glutathione peroxidase overexpression inhibits cytochrome c release and proapoptotic mediators to protect neurons from experimental stroke. Stroke 34: 2489-2494, 2003.
56. Inoue H, Tsukita K, Iwasato T, Suzuki Y, Tomioka M, Tateno M, Nagao M, Kawata A, Saido TC, Miura M, Misawa H, Itohara S, and Takahashi R. The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J 22: 6665-6674, 2003.
57. Jana NR, Zemskov EA, Wang GH, and Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10: 1049-1059, 2001.
58. Jiang X, Tian F, Mearow K, Okagaki P, Lipsky RH, and Marini AM. The excitoprotective effect of N-methyl-D-aspartate receptors is mediated by a brain-derived neurotrophic factor autocrine loop in cultured hippocampal neurons. J Neurochem 94: 713-722, 2005.
59. Kaspar BK, Llado J, Sherkat N, Rothstein JD, and Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839-842, 2003.
60. Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, and Mattson MP. ndrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 18: 687-697, 1998.
61. Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, and Ferrante RJ. Cytochrome c and caspase-9 expression in Huntington's disease. Neuromol Med 1: 183-195, 2002.
62. Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JR Jr., Friedlander RM, and Beal MF. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 10: 635-638, 1999.
63. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, and Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5: 347-350, 1999.
64. Kruman I, Bruce-Keller AJ, Bredesen E, Waeg G, and Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci 17: 5089-5100, 1997.
65. Kruman II, Pedersen WA, Springer JE, and Mattson MP. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol 160: 28-39, 1999.
66. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, and Mattson MP. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22: 1752-1762, 2002.
67. Kruman II, Schwartz E, Kruman Y, Cutler RG, Zhu X, Greig NH, and Mattson MP. Suppression of uracil-DNA glycosylase induces neuronal apoptosis. J Biol Chem 279: 43952-43960, 2004.
68. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mimics K, and Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120: 701-713, 2005.
69. Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, and Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498, 2001.
70. Lee J, Duan W, and Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 82: 1367-1375, 2000.
71. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, and Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288: 335-339, 2000.
72. Lindsten T, Zong WX, and Thompson CB. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 11: 10-15, 2005.
73. Lopez-Neblina F, Toledo AH, and Toledo-Pereyra LH. Molecular biology of apoptosis in ischemia and reperfusion. J Invest Surg 18: 335-350, 2005.
74. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, and Dawson TM. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 96: 5774-5779, 1999.
75. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 58: 459-471, 1999.
76. Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol Dis 7: 613-622, 2000.
77. Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, Grondin R, Roth GS, Mattison J, Lane MA, Carson RE, Cohen RM, Mouton PR, Quigley C, Mattson MP, and Ingram DK. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 18171-18176, 2004.
78. Mattson MP, Lovell MA, Furukawa K, and Markesbery WR. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 65: 1740-1751, 1995.
79. Mattson MP, Partin J, and Begley JG. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 807: 167-176, 1998.
80. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1: 120-129, 2000.
81. Mattson MP, Culmsee C, and Yu ZF. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res 301: 173-187, 2000.
82. Mattson MP, Chan SL, and Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 82: 637-672, 2002.
83. Mattson MP and Kroemer G. Mitochondria in cell death: novel targets for neuro- and cardio-protection. Trends Mol Med 9: 196-205, 2003.
84. Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 3: 65-94, 2003.
85. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639, 2004.
86. Mattson MP, Maudsley S, and Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27: 589-594, 2004.
87. Mattson MP and Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 6: [Epub ahead of print], 2006.
88. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 26: 81-104, 2003.
89. Miller RG, Mitchell JD, Lyon M, and Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4: 191-206, 2003.
90. Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. J Biol Chem 280: 22530-22539, 2005.
91. Moechars D, Lorent K, and Van Leuven F. Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience 91: 819-830, 1999.
92. Moos T and Jensen PH. Absence of prostate apoptosis response-4 protein in substantia nigra of Parkinson's disease autopsies. Acta Neuropathol (Berl) 107: 23-26, 2004.
93. Mu Z, He J, Anderson DW, Trojanowski JQ, and Springer JE. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol 40: 379-386, 1996.
94. Nandagopal K, Dawson TM, and Dawson VL. Critical role for nitric oxide signaling in cardiac and neuronal ischemic preconditioning and tolerance. J Pharmacol Exp Ther 297: 474-478, 2001.
95. Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, and Buisson A. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci 21: 3024-3033, 2001.
96. Niikura T, Hashimoto Y, Okamoto T, Abe Y, Yasukawa T, Kawasumi M, Hiraki T, Kita Y, Terashita K, Kouyama K, and Nishimoto I. Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J Neurosci 21: 1902-1910, 2001.
97. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, and LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421, 2003.
98. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, and Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A 95: 5789-5794, 1998.
99. Okado-Matsumoto A and Fridovich I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc Natl Acad Sci U S A 99: 9010-9014, 2002.
100. Oppenheim RW, Houenou LJ, Johnson JE, Lin LF, Li L, Lo AC, Newsome AL, Prevette DM, and Wang S. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 373: 344-346, 1995.
101. Paradis E, Douillard H, Koutroumanis M, Goodyer C, and LeBlanc A. Amyloid beta peptide of Alzheimer's disease down-regulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci 16: 7533-7539, 1996.
102. Pasinelli P, Borchelt DR, Houseweart MK, Cleveland DW, and Brown RH Jr. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci U S A 95: 15763-15768, 1998.
103. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, and Brown RH Jr. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43: 19-30, 2004.
104. Patel NV, Gordon MN, Connor KE, Good RA, Engelman RW, Mason J, Morgan DG, Morgan TE, and Finch CE. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging 26: 995-1000, 2005.
105. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, and Mattson MP. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 44: 819-824, 1998.
106. Pedersen WA, Chan SL, and Mattson MP. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem 74: 1426-1433, 2000.
107. Perrelet D, Ferri A, Liston P, Muzzin P, Korneluk RG, and Kato AC. IAPs are essential for GDNF-mediated neuroprotective effects in injured motor neurons in vivo. Nat Cell Biol 4: 175-179, 2002.
108. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, and Beal MF. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2005 Nov 10; [Epub ahead of print]
109. Portera-Cailliau C, Hedreen JC, Price DL, and Koliatosos VE. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 15: 3775-3787, 1995.
110. Putcha GV and Johnson EM Jr. Men are but worms: neuronal cell death in C. elegans and vertebrates. Cell Death Differ 11: 38-48, 2004.
111. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, and Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13: 1225-1240, 2004.
112. Riccio A, Ahn S, Davenport CM, Blendy JA, and Ginty DD. Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286: 2358-2361, 1999.
113. Robertson GS, Crocker SJ, Nicholson DW, et al. Neuroprotection by the inhibition of apoptosis. Brain Pathol 10: 283-292, 2000
114. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, and Cribbs DH. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158: 189-198, 2001.
115. Rohn T, Rissman RA, Davis MC, Kim YE, Cotman CW, and Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis 11: 341-354, 2002.
116. Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet 18: 202-209, 2002.
117. Russo VC, Kobayashi K, Najdovska S, Baker NL, and Werther GA. Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system. Brain Res 1009: 40-53, 2004.
118. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, and Ross CA. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5: 1194-1198, 1999.
119. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, and Burke D; NEALS Consortium. A clinical trial of creatine in ALS. Neurology 63: 1656-1661, 2004.
120. Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, Gale A, Neslon C, Chan N, Eaton M, Fromholt D, Ross CA, and Borchelt DR. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 187: 137-149, 2004.
121. Sharp FR, Lu A, Tang Y, Millhorn DE. Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 20: 1011-1032, 2000.
122. Sieradzan KA and Mann DM. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol 27: 1-21, 2001.
123. Stefanis L. Caspase-dependent and -independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist 11: 50-62, 2005.
124. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, and Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24: 7707-7717, 2004.
125. Su JH, Deng G, and Cotman CW. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 56: 86-93, 1997.
126. Sugawara T, Fujimura M, Noshita N, Kim GW, Saito A, Hayashi T, Narasimhan P, Maier CM, and Chan PH. Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 1: 17-25, 2004.
127. Sun F, Anatharam V, Latchoumycandane C, Kanthasamy A, and Kanthasamy AG. Dieldrin induces ubiquitin-proteasome dysfunction in alphα-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. J Pharmacol Exp Ther 315: 69-79, 2005.
128. Tamagno E, Parola M, Guglielmotto M, Santoro G, Bardini P, Marra L, Tabaton M, and Danni O. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic Biol Med 35: 45-58, 2003.
129. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa AL, Dawson V, Dawson TM, and Ross CA. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria- dependent apoptosis. Hum Mol Genet 10: 919-926, 2001.
130. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, and Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 102: 2602-2607, 2005.
131. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166: 29-43, 2000.
132. Tatton WG, Chalmers-Redman R, Brown D, and Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 53: S61-S70, 2003.
133. Thiruchelvam M, Prokopenko O, Cory-Slechta DA, Richfield EK, Buckley B, Kobayashi Y, Kume A, Li M, Doyu M, Hata M, Ohtsuka K, and Sobue G. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 275: 8772-8778, 2000.
134. Toledano A and Alvarez MI. Lesions and dysfunctions of the nucleus basalis as Alzheimer's disease models: general and critical overview and analysis of the long-term changes in several excitotoxic models. Curr Alzheimer Res 1: 189-214, 2004.
135. Vila M and Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4: 365-375, 2003.
136. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 2837-2842, 2001.
137. Vis JC, Schipper E, de Boer-van Huizen RT, Verbeek MM, de Waal RM, Wesseling P, ten Donkelaar HJ, and Kremer B. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol (Berl) 109: 321-328, 2005.
138. Vukosavic S, Stefanis L, Jackson-Lewis V, Guegan C, Romero N, Chen C, Dubois-Dauphin M, and Przedborski S. Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 20: 9119-9125, 2000.
139. Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative disorders. Prog Neuropsychopharmacol Biol Psychiatry 27: 303-321, 2003.
140. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, and Friedlander RM. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100: 10483-10487, xxxx.
141. West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita SP, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, West S, Williamson KS, Zemlan F, and Hensley K. The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem 91: 133-143, 2004.
142. Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, and Schulz JB. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J Neurosci 22: 6401-6407, 2002.
143. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16: 921-932, 1996.
144. Yu Z, Luo H, Fu W, and Mattson MP. The endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: suppression of oxidative stress and stabilization of calcium homeostasis. Exp Neurol 155: 302-314, 1999.
145. Yu Z, Zhou D, Cheng G, and Mattson MP. Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. J Mol Neurosci 15: 31-44, 2000.
146. Yuan Y, Lipinski M, and Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron 40: 401-413, 2003.
147. Zheng Z, Zhao H, Steinberg GK, and Yenari MA. Cellular and molecular events underlying ischemia-induced neuronal apoptosis. Drug News Perspect 16: 497-503, 2003.
148. Zhou ZD, Yap BP, Gung AY, Leong SM, Ang ST, and Lim TM. Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant alphα-synuclein. Exp Cell Res 312: 156-170, 2006.